A daily dose of Relay Therapeutics’ experimental drug for cholangiocarcinoma, a rare cancer of the bile ducts, led to tumor shrinkage of a third or more in 15 of 17 patients with metastatic disease, the company said Wednesday.
The results were released in an abstract at the annual meeting of the European Society of Molecular Oncology, where they will be presented in full on Sunday.
Relay’s drug, known as RLY-4008, works only in tumors that have a particular kind of mutation related to a gene for a protein called FGFR2. Other drugs exist for treating cholangiocarcinoma patients with this mutation, but doctors believe their efficacy is limited by toxicities, including high levels of phosphorus, that prevent researchers from giving them in high enough doses.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect